🔗 Share this article

This year's Nobel Prize in Physiology or Medicine has been awarded for transformative findings that illuminate how the body's defense network targets dangerous infections while sparing the healthy tissues.

A trio of renowned scientists—from Japan Prof. Sakaguchi and American experts Dr. Brunkow and Fred Ramsdell—received this accolade.

Their work identified unique "security guards" within the immune system that eliminate rogue immune cells capable of attacking the organism.

The discoveries are now enabling innovative treatments for autoimmune diseases and cancer.

These laureates will share a monetary award worth 11m Swedish kronor.

Decisive Findings

"The research has been essential for understanding how the body's defenses operates and the reason we don't all suffer from serious autoimmune diseases," stated the chair of the Nobel Committee.

The trio's research address a core mystery: How does the immune system protect us from numerous infections while leaving our own tissues intact?

The immune system uses immune cells that search for signs of disease, even pathogens and germs it has never encountered.

Such cells employ detectors—called receptors—that are produced by chance in a vast number of variations.

That provides the defense network the ability to combat a wide array of threats, but the unpredictability of the process unavoidably produces white blood cells that may attack the host.

Security Guards of the Body

Researchers previously knew that a portion of these problematic white blood cells were eliminated in the thymus—the site where white blood cells develop.

This year's award honors the discovery of regulatory T-cells—known as the body's "peacekeepers"—which patrol the system to disarm other defenders that assault the body's own tissues.

We know that this mechanism malfunctions in self-attack conditions such as type-1 diabetes, MS, and rheumatoid arthritis.

A Nobel panel added, "The findings have laid the foundation for a novel area of research and accelerated the development of new therapies, for example for cancer and autoimmune diseases."

Regarding malignancies, regulatory T-cells block the body from fighting the growth, so research are aimed at lowering their quantity.

In autoimmune diseases, experiments are testing boosting regulatory T-cells so the body is no longer being harmed. A comparable method could also be effective in reducing the risks of transplanted organ rejection.

Pioneering Experiments

Prof Shimon Sakaguchi, of Osaka University, conducted tests on rodents that had their immune gland extracted, causing autoimmune disease.

He showed that injecting immune cells from healthy animals could prevent the illness—implying there was a system for blocking defenders from harming the host.

Mary Brunkow, affiliated with the a research center in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were investigating an genetic autoimmune disease in rodents and people that led to the discovery of a genetic factor vital for how regulatory T-cells operate.

"The groundbreaking work has revealed how the immune system is kept in check by regulatory T cells, preventing it from mistakenly attacking the body's own tissues," said a leading biological science specialist.

"This work is a striking illustration of how basic biological research can have far-reaching implications for public health."